Compare IDEXX Laboratories, Inc. (IDXX) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs VNET Group Inc — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while VNET Group Inc trades at $7.52 (market cap $2.14B). The key difference: IDEXX Laboratories, Inc. is far larger — about 21.6× VNET Group Inc's market cap. Which is the better fit depends on your goals.
| IDXX | VNET | |
|---|---|---|
Market Cap | $46.22B | $2.14B |
Sector | Health | Technology |
52-Week High | $766.68 | $14.03 |
52-Week Low | $526.44 | $6.29 |
Enterprise Value | $47.12B | $5.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
VNET Group trades at $7.425, down 0.74% on the day, with a neutral technical signal and mixed earnings history. The stock shows a price-to-sales ratio of 1.32 and an EV/EBITDA of 26.51, but profitability remains weak with a net income margin of -21.63% and negative ROE. Recent news highlights large call option purchases and upcoming Q2 2026 earnings on August 18, 2026, amid strategic investor involvement.
The outlook is cautiously optimistic due to strong analyst buy ratings (62.5%) and AI-driven demand growth, but significant risks include persistent losses, high debt levels, and competitive pressures in China's data center market. Investors should weigh the potential from new capacity against execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
